Biden Admin Takes $3.9 Billion Risk on Monkeypox Vaccine!

Published on September 6, 2022

The Biden administration is embarking on an ambitious mission, akin to making a daring bet worth billions, to combat the monkeypox outbreak. Drawing inspiration from the world of casinos, they’re going all-in by repurposing a vaccine initially developed for smallpox. Like a poker player pushing their chips into the center of the table, they’re wagering that this gamble will pay off in saving lives. What makes this move even more heart-pounding is that the vaccine will be distributed without the usual human trials, raising stakes and intensifying excitement.

As we await the results of this high-stakes game, scientists ponder potential outcomes. Will the smallpox vaccine prove effective against monkeypox? Could this alternative use of the vaccine revolutionize our approach to combating infectious diseases? Only time will tell. In the meantime, let’s dive deeper into the research behind the vaccine and see why it has caught the attention of the Biden administration. Together, we can unravel the mysteries of this unprecedented risk and discover how science is adapting to tackle new challenges and keep us safe.

The Biden administration is hoping — potentially to the tune of $3.9 billion — that a vaccine designed to prevent smallpox can work to save lives against the monkeypox outbreak, sending it out without human trials.

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>